inhibitory effects of salinispora-derived metabolites against multidrug resistance: an in-silico study

Background: multi drug resistance (mdr) is known to defeat most chemotherapies as one of the main anticancer strategies. the role of overexpression or overactivation of atpbinding cassette (abc) transporters, especially pglycoprotein (p-gp), in the development of chemotherapy has long been demonstrated. salinispora is a marine actinomycete genus known for the production of novel bioactive metabolites.objectives: in this study, the potential of salinispora derived metabolites as inhibitor of atpbinding cassette (abc) transports have been investigated using insilico approaches.methods: physicochemical, pharmacokinetic and drug likeness of the salinispora derived metabolites have been analyzed using swiss adme server. this was accompanied by the employment of docking strategy to evaluate anti-mdr potential of the metabolites using pgp, breast cancer resistance protein (bcrp) and multidrug resistance protein 1 (mrp-1) as target proteins. results: nineteen metabolites were found to have demonstrated appropriate physicochemical, pharmacokinetic, and druglikeness properties and were involved in the docking studies. based on docking studies, saliniquinones, cyclomarazine, and cyanosporoside a demonstrated abc transporters inhibitory potential.conclusion: our results suggest that further in vivo and in vitro studies on anti-mdr effects of salinisporaderived metabolites are warranted.